名臣健康(002919) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 361,419,226.73, a slight decrease of 0.10% compared to CNY 361,783,077.71 in the same period last year[5]. - Net profit attributable to shareholders decreased by 71.62% to CNY 12,713,011.49 from CNY 44,792,608.81 year-on-year[5]. - Basic and diluted earnings per share dropped by 70.59% to CNY 0.05 from CNY 0.17 in the same quarter last year[5]. - Operating profit decreased to ¥14,774,308.45, down 69.4% from ¥48,268,573.56 in the previous period[22]. - Net profit for the current period is ¥12,747,632.76, a significant decline of 71.5% from ¥44,792,608.81 in the previous period[22]. Cash Flow - The net cash flow from operating activities was negative CNY 52,846,010.99, a decline of 70.72% compared to negative CNY 30,954,318.55 in the previous year[13]. - Cash inflow from operating activities totaled ¥267,700,532.63, down from ¥284,521,640.80 in the previous period[24]. - The net cash flow from investment activities was -$1.71 million, improving from -$22.17 million year-over-year[25]. - Total cash outflow from operating activities was $320.55 million, compared to$315.48 million previously, showing stable operational cash outflows[25]. Assets and Liabilities - Total assets increased by 1.49% to CNY 1,119,796,609.12 from CNY 1,103,346,118.01 at the end of the previous year[5]. - The total current assets are 661,593,066.07 yuan, down from 690,847,376.26 yuan at the beginning of the period[18]. - The total liabilities include accounts payable of 152,860,463.00 yuan, which increased from 127,066,568.53 yuan, a rise of about 20.3%[18]. - Total liabilities increased to ¥283,712,534.47 from ¥280,009,676.12 in the previous period[19]. Operating Costs and Expenses - The company reported a 27.34% increase in operating costs, rising to CNY 157,926,236.96 from CNY 124,018,992.61, primarily due to the launch of multiple games[11]. - Total operating costs increased to ¥340,518,894.23, up 10.9% from ¥306,836,632.03 in the previous period[21]. - Research and development expenses decreased by 30.34% to CNY 13,676,400.02 from CNY 19,631,760.74, attributed to project optimization and team streamlining[11]. - Research and development expenses decreased to ¥13,676,400.02, down 30.5% from ¥19,631,760.74 in the previous period[22]. Shareholder Information - The company's total equity attributable to shareholders increased by 1.54% to CNY 836,051,909.31 from CNY 823,338,897.82 at the end of the previous year[5]. - The total number of common shareholders at the end of the reporting period is 18,272[14]. - The largest shareholder, Chen Qinfang, holds 35.02% of shares, totaling 93,338,604 shares, with 11,644,000 shares pledged[14]. Other Information - The company has no preferred shareholders as of the reporting period[16]. - The first quarter report was not audited, which may affect the reliability of the financial data presented[27]. - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[26]. - The company did not execute any significant acquisitions or new product launches during this reporting period[27].